Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study

被引：0
|
作者：
Cliff Molife
Katherine B. Winfree
Hollie Bailey
Yulia D’yachkova
Cameron Forshaw
Sangmi Kim
Kaisa-Leena Taipale
Tarun Puri
机构：
[1] Eli Lilly and Company,Value, Evidence, and Outcomes
[2] Lilly Corporate Center,Oncology
[3] Adelphi Real World,Lilly International Medical Affairs Oncology
[4] Statistics,undefined
[5] Eli Lilly and Company,undefined
[6] Global Patient Safety-Pharmacoepidemiology,undefined
[7] Eli Lilly and Company,undefined
[8] Value,undefined
[9] Evidence,undefined
[10] and Outcomes-International,undefined
[11] Eli Lilly and Company,undefined
[12] Eli Lilly and Company,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Advanced non-small cell lung cancer; Disease Specific Programme™; mutation; Patient-reported outcomes; Point-in-time; Real-world; Survey; Treatment patterns;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3135 / 3168
页数：33
相关论文
共 50 条
  • [31] Real World Treatment and Outcomes in EGFR-mutated Advanced Non-small Cell Lung Cancer Patients: A Nationwide Cohort for 1,932 Thai Patients
    Tienchai, K.
    Sa-nguansai, S.
    Payapwattanawong, S.
    Tienchaiananda, P.
    Maneenil, K.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S440 - S441
  • [32] High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
    Chen, Haiyang
    Wang, Lili
    Wu, Yingxi
    Wu, Yufeng
    Ma, Shuxiang
    Yang, Sen
    He, Zhen
    Mo, Yuqing
    Zhang, Cuicui
    Wang, Qiming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
    Mambetsariev, Isa
    Arvanitis, Leonidas
    Fricke, Jeremy
    Pharaon, Rebecca
    Baroz, Angel R.
    Afkhami, Michelle
    Koczywas, Marianna
    Massarelli, Erminia
    Salgia, Ravi
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (05)
  • [34] Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations
    Chen, Chi-Han
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Hsu, Ping-Chih
    Wu, Chiao-En
    ANTICANCER RESEARCH, 2022, 42 (04) : 2145 - 2157
  • [35] A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
    Chun-Yao Huang
    Hui-Li Huang
    Chou-Chin Lan
    Yi-Chih Huang
    Yao-Kuang Wu
    BMC Cancer, 23
  • [36] Progression of leptomeningeal metastases in advanced EGFR-mutated non-small cell lung cancer
    Zhao, Q.
    Deng, L.
    Zhang, Y.
    Zhou, X.
    Li, Y.
    Yu, M.
    Zhou, L.
    Zou, B.
    Liu, Y.
    Lu, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Adjuvant aumolertinib in resected EGFR-mutated non-small cell lung cancer: A multiple-center real-world experience
    Zhang, Q.
    Ke, L.
    Huang, S.
    Yang, Y.
    He, T.
    Sun, H.
    Wu, Z.
    Zhang, X.
    Zhang, H.
    Lv, W.
    Hu, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S98 - S98
  • [38] Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases
    Yu, Xiaoqing
    Sheng, Jiamin
    Pan, Guoqiang
    Fan, Yun
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (05) : 1121 - 1128
  • [39] Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Pereira, Isabel
    Gaspar, Catia
    Pina, Marta
    Azevedo, Isabel
    Rodrigues, Ana
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (12)
  • [40] Emerging drugs for EGFR-mutated non-small cell lung cancer
    Sukrithan, Vineeth
    Deng, Lei
    Barbar, Alexander
    Cheng, Haiying
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (01) : 5 - 16
12345